68Ga-somatostatin analogue PET-CT: Analysis of costs and benefits in a public hospital setting

Tatiana Segard, Laurence M.J.A. Morandeau, Elizabeth A. Geelhoed, Roslyn J. Francis

Research output: Contribution to journalArticle

Abstract

Introduction: Between 2009 and 2012, 68Ga-somatostatin analogue PET-CT progressively replaced 111In-octreotide scintigraphy for imaging neuroendocrine tumours in WA public hospitals due to published literature demonstrating improved diagnostic accuracy and increased availability. Despite significantly improved sensitivity and specificity, 68Ga-somatostatin analogue PET is currently unfunded in Australia. This study sought to undertake cost analysis of the two modalities in a public hospital setting and to compare them with regard to patient factors such as imaging time and radiation dose. Methods: This analysis was based on retrospective clinical data from 95 111In-octreotide scintigraphies performed in 2007 and 2008 at Sir Charles Gairdner (SCGH) and Royal Perth (RPH) hospitals and 219 68Ga-somatostatin analogue PET-CT studies performed in 2013 at SCGH. Whole body effective radiation dose was derived from the radiopharmaceutical and low-dose CT scan. The cost analysis included radiopharmaceutical and imaging costs. Results: The median imaging time for an 111In-octreotide scintigraphy was 152 min at SCGH, 100 min at RPH and 20 min for a 68Ga-somatostatin analogue PET-CT scan. The mean effective radiation dose for 111In-octreotide scintigraphy was 18.1 mSv at SCGH and 13.8 mSv at RPH. The effective dose for 68Ga-somatostatin analogue PET-CT was 8.7–10.8 mSv. The average cost of 68Ga-somatostatin analogue PET-CT was four times less than 111In-octreotide scintigraphy. Conclusion: 68Ga-somatostatin analogue PET-CT is not only more accurate than 111In-octreotide scintigraphy, this study has also shown that it is significantly less expensive, delivers a lower radiation dose to patients and requires less imaging time for patients and staff. 68Ga-somatostatin PET-CT provides an important combination of both reduced cost and improved clinical care for patients.

Original languageEnglish
Pages (from-to)57-63
Number of pages7
JournalJournal of Medical Imaging and Radiation Oncology
Volume62
Issue number1
DOIs
Publication statusPublished - 1 Feb 2018

Fingerprint

Public Hospitals
Somatostatin
Cost-Benefit Analysis
Radionuclide Imaging
Costs and Cost Analysis
Radiation
Neuroendocrine Tumors
Radiopharmaceuticals
Positron Emission Tomography Computed Tomography
Whole-Body Irradiation
indium-111-octreotide
Patient Care
Sensitivity and Specificity

Cite this

@article{0eb4940f5f8e4307920f70071f58b0ae,
title = "68Ga-somatostatin analogue PET-CT: Analysis of costs and benefits in a public hospital setting",
abstract = "Introduction: Between 2009 and 2012, 68Ga-somatostatin analogue PET-CT progressively replaced 111In-octreotide scintigraphy for imaging neuroendocrine tumours in WA public hospitals due to published literature demonstrating improved diagnostic accuracy and increased availability. Despite significantly improved sensitivity and specificity, 68Ga-somatostatin analogue PET is currently unfunded in Australia. This study sought to undertake cost analysis of the two modalities in a public hospital setting and to compare them with regard to patient factors such as imaging time and radiation dose. Methods: This analysis was based on retrospective clinical data from 95 111In-octreotide scintigraphies performed in 2007 and 2008 at Sir Charles Gairdner (SCGH) and Royal Perth (RPH) hospitals and 219 68Ga-somatostatin analogue PET-CT studies performed in 2013 at SCGH. Whole body effective radiation dose was derived from the radiopharmaceutical and low-dose CT scan. The cost analysis included radiopharmaceutical and imaging costs. Results: The median imaging time for an 111In-octreotide scintigraphy was 152 min at SCGH, 100 min at RPH and 20 min for a 68Ga-somatostatin analogue PET-CT scan. The mean effective radiation dose for 111In-octreotide scintigraphy was 18.1 mSv at SCGH and 13.8 mSv at RPH. The effective dose for 68Ga-somatostatin analogue PET-CT was 8.7–10.8 mSv. The average cost of 68Ga-somatostatin analogue PET-CT was four times less than 111In-octreotide scintigraphy. Conclusion: 68Ga-somatostatin analogue PET-CT is not only more accurate than 111In-octreotide scintigraphy, this study has also shown that it is significantly less expensive, delivers a lower radiation dose to patients and requires less imaging time for patients and staff. 68Ga-somatostatin PET-CT provides an important combination of both reduced cost and improved clinical care for patients.",
keywords = "Gallium-68, neuroendocrine tumours, PET-CT, somatostatin analogues",
author = "Tatiana Segard and Morandeau, {Laurence M.J.A.} and Geelhoed, {Elizabeth A.} and Francis, {Roslyn J.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1111/1754-9485.12638",
language = "English",
volume = "62",
pages = "57--63",
journal = "Journal of Medical Imaging and Radiation Oncology",
issn = "0004-8461",
publisher = "John Wiley & Sons",
number = "1",

}

68Ga-somatostatin analogue PET-CT : Analysis of costs and benefits in a public hospital setting. / Segard, Tatiana; Morandeau, Laurence M.J.A.; Geelhoed, Elizabeth A.; Francis, Roslyn J.

In: Journal of Medical Imaging and Radiation Oncology, Vol. 62, No. 1, 01.02.2018, p. 57-63.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 68Ga-somatostatin analogue PET-CT

T2 - Analysis of costs and benefits in a public hospital setting

AU - Segard, Tatiana

AU - Morandeau, Laurence M.J.A.

AU - Geelhoed, Elizabeth A.

AU - Francis, Roslyn J.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Introduction: Between 2009 and 2012, 68Ga-somatostatin analogue PET-CT progressively replaced 111In-octreotide scintigraphy for imaging neuroendocrine tumours in WA public hospitals due to published literature demonstrating improved diagnostic accuracy and increased availability. Despite significantly improved sensitivity and specificity, 68Ga-somatostatin analogue PET is currently unfunded in Australia. This study sought to undertake cost analysis of the two modalities in a public hospital setting and to compare them with regard to patient factors such as imaging time and radiation dose. Methods: This analysis was based on retrospective clinical data from 95 111In-octreotide scintigraphies performed in 2007 and 2008 at Sir Charles Gairdner (SCGH) and Royal Perth (RPH) hospitals and 219 68Ga-somatostatin analogue PET-CT studies performed in 2013 at SCGH. Whole body effective radiation dose was derived from the radiopharmaceutical and low-dose CT scan. The cost analysis included radiopharmaceutical and imaging costs. Results: The median imaging time for an 111In-octreotide scintigraphy was 152 min at SCGH, 100 min at RPH and 20 min for a 68Ga-somatostatin analogue PET-CT scan. The mean effective radiation dose for 111In-octreotide scintigraphy was 18.1 mSv at SCGH and 13.8 mSv at RPH. The effective dose for 68Ga-somatostatin analogue PET-CT was 8.7–10.8 mSv. The average cost of 68Ga-somatostatin analogue PET-CT was four times less than 111In-octreotide scintigraphy. Conclusion: 68Ga-somatostatin analogue PET-CT is not only more accurate than 111In-octreotide scintigraphy, this study has also shown that it is significantly less expensive, delivers a lower radiation dose to patients and requires less imaging time for patients and staff. 68Ga-somatostatin PET-CT provides an important combination of both reduced cost and improved clinical care for patients.

AB - Introduction: Between 2009 and 2012, 68Ga-somatostatin analogue PET-CT progressively replaced 111In-octreotide scintigraphy for imaging neuroendocrine tumours in WA public hospitals due to published literature demonstrating improved diagnostic accuracy and increased availability. Despite significantly improved sensitivity and specificity, 68Ga-somatostatin analogue PET is currently unfunded in Australia. This study sought to undertake cost analysis of the two modalities in a public hospital setting and to compare them with regard to patient factors such as imaging time and radiation dose. Methods: This analysis was based on retrospective clinical data from 95 111In-octreotide scintigraphies performed in 2007 and 2008 at Sir Charles Gairdner (SCGH) and Royal Perth (RPH) hospitals and 219 68Ga-somatostatin analogue PET-CT studies performed in 2013 at SCGH. Whole body effective radiation dose was derived from the radiopharmaceutical and low-dose CT scan. The cost analysis included radiopharmaceutical and imaging costs. Results: The median imaging time for an 111In-octreotide scintigraphy was 152 min at SCGH, 100 min at RPH and 20 min for a 68Ga-somatostatin analogue PET-CT scan. The mean effective radiation dose for 111In-octreotide scintigraphy was 18.1 mSv at SCGH and 13.8 mSv at RPH. The effective dose for 68Ga-somatostatin analogue PET-CT was 8.7–10.8 mSv. The average cost of 68Ga-somatostatin analogue PET-CT was four times less than 111In-octreotide scintigraphy. Conclusion: 68Ga-somatostatin analogue PET-CT is not only more accurate than 111In-octreotide scintigraphy, this study has also shown that it is significantly less expensive, delivers a lower radiation dose to patients and requires less imaging time for patients and staff. 68Ga-somatostatin PET-CT provides an important combination of both reduced cost and improved clinical care for patients.

KW - Gallium-68

KW - neuroendocrine tumours

KW - PET-CT

KW - somatostatin analogues

UR - http://www.scopus.com/inward/record.url?scp=85024886643&partnerID=8YFLogxK

U2 - 10.1111/1754-9485.12638

DO - 10.1111/1754-9485.12638

M3 - Article

VL - 62

SP - 57

EP - 63

JO - Journal of Medical Imaging and Radiation Oncology

JF - Journal of Medical Imaging and Radiation Oncology

SN - 0004-8461

IS - 1

ER -